Descriptive analysis of haemangiosarcoma occurrence in dogs enrolled in the Golden Retriever lifetime study

Abstract Haemangiosarcoma is a relatively common malignant tumour in dogs, and one of the primary outcomes of interest for the Golden Retriever Lifetime Study. This study collects longitudinal data and samples from a cohort of golden retrievers, with the aim of identification of nutritional, genetic, environmental, lifestyle and reproductive risk factors for cancers and other important diseases in dogs. This analysis describes the accumulating data and samples, which are available for use by researchers to fulfil the study's objectives. As of September 2022, 233/3044 dogs enrolled in the study had been diagnosed with haemangiosarcoma (7.65%), with an incidence rate of 1.10 cases per 100 dog‐years. Visceral haemangiosarcoma was the most common, affecting 211/3044 study dogs (6.9%). One hundred and twenty eight visceral haemangiosarcoma diagnoses specified the presence of splenic tumours (60.7%) and 119 specified the presence of cardiac tumours (56.4%). The probability of remaining without a haemangiosarcoma diagnosis declined from 100% from approximately 4 years of age, to a 12 year probability of 91.1% in intact females (95% CI 84.4%–98.3%), 60.7% in neutered females (95% CI 41.6%–88.6%), 72.9% in intact males (95% CI 62.9%–84.6%) and 70.0% in neutered males (95% CI 53.4%–92.0%). The 1 year survival probability for visceral haemangiosarcoma was 1.42% (95% CI 0.37%–5.47%); for cutaneous haemangiosarcoma, it was 84.6% (95% CI 67.1%–99.99%). The accumulated data and samples are a considerable resource for further investigation of canine haemangiosarcoma and have a potential role in translational medicine.